NCT06558786Recruiting
Registry for Esophageal and Gastroesophageal Junction Cancer
Prospective Registry Study of Multimodality Therapy for Oligometastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
The purpose of this registry study is to create a database-a collection of information-for better understanding standard treatments for esophageal and Gastroesophageal Junction Cancer/GEJ cancer. Researchers will use the information from this database to learn more about the effectiveness of different treatment options.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 13 Aug 2024
- Start date
- 12 Aug 2024
- Primary completion date
- 12 Aug 2029
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06558786
What you commit to
- Study type: Observational
- Planned participants: 50
- From 12 Aug 2024 to the primary completion date, 12 Aug 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unfit for best systemic therapy
Other illness
- Presence of metastases, at the time of diagnosis, to the following:
- Peritoneum, including positive peritoneal lavage (on the basis of baseline diagnostic laparoscopy to rule out gross disease and positive peritoneal lavage cytology; laparoscopy may be omitted for patients in whom all sites of disease are above the diaphragm)
- Malignant pleural effusion
- Brain metastases or leptomeningeal disease
- Other sites not specifically noted must be reviewed and approved by the PIs
- Any site of disease that is not amenable to definitive local therapy
- Secondary primary cancer, with the exclusion of basal cell carcinoma of the skin
Other
- Metachronous OMD
- Pregnant, lactating, or intending to become pregnant
- Unwilling to provide informed consent
Who the study is looking for
- Newly diagnosed stage IV adenocarcinoma of the esophagus or GEJ with OMD at the time of diagnosis, defined as the following:
- Retroperitoneal lymph nodes (e.g., para-aortal, intra-aorto-caval, parapancreatic, or mesenterial lymph node)
- Liver
- Lung
- Extra-abdominal lymph nodes (e.g., supraclavicular or cervical lymph nodes)
- Adrenal gland
- Unilateral or bilateral ovarian metastases (in the absence of gross or microscopic peritoneal disease \[positive cytology\])
- Bone
- ≤2 sites of disease (excluding the primary tumor and regional lymph nodes)
- ≤3 tumors within each organ system
- ≤5 metastases
- All nonregional lymph nodes (including cervical, supraclavicular, and retroperitoneal nodal disease) are considered 1 discrete lesion
- Satellite lesions in the primary esophageal malignancy, such as skipped esophageal primaries, are not considered metastatic sites
- All sites of disease must be amenable to complete local therapy after systemic therapy, according to the treating physician. Treatment modalities include:
- Surgery
- Definitive chemoradiation
- Stereotactic radiation
- Ablation or similar techniques (e.g., irreversible electroporation)
- Age ≥18 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.